| Citation: |
AI Xing-hao, LU Shun. Can Patients With Advanced NSCLC Enjoy "Drug Holiday"?----Comment on the Adaptive De-Escalate Treatment of Targeted Drugs Guided by ctDNA in Patients With Advanced NSCLC[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 135-137. DOI: 10.12019/j.issn.1671-5144.202406017
|
| [1] |
SORIA J C, OHE Y, VANSTEENKISTE J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113−125. doi: 10.1056/NEJMoa1713137.
|
| [2] |
PETERS S, CAMIDGE D R, SHAW A T, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(9): 829−838. doi: 10.1056/NEJMoa1704795.
|
| [3] |
XU Q H, ZHOU F, LIU H, et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs[J]. J Thorac Oncol, 2018, 13(9): 1383−1392. doi: 10.1016/j.jtho.2018.05.019.
|
| [4] |
ELAMIN Y Y, GOMEZ D R, ANTONOFF M B, et al. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small-cell lung cancer (NSCLC)[J]. Clin Lung Cancer, 2019, 20(1): 43−47. doi: 10.1016/j.cllc.2018.09.015.
|
| [5] |
DONG S, WANG Z, ZHANG J T, et al. Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized clinical trial[J]. JAMA Oncol, 2024. doi: 10.1001/jamaoncol.2024.1779.
|
| [6] |
MAUGHAN T S, JAMES R D, KERR D J, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial[J]. Lancet, 2003, 361(9356): 457−464. doi: 10.1016/S0140-6736(03)12461-0.
|
| [7] |
CHIBAUDEL B, MAINDRAULT-GOEBEL F, LLEDO G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study[J]. J Clin Oncol, 2009, 27(34): 5727−5733. doi: 10.1200/JCO.2009.23.4344.
|
| [8] |
LE CESNE A, RAY-COQUARD I, BUI B N, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(10): 942−949. doi: 10.1016/S1470-2045(10)70222-9.
|
| [9] |
BROWN J E, ROYLE K L, GREGORY W, et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial[J]. Lancet Oncol, 2023, 24(3): 213−227. doi: 10.1016/S1470-2045(22)00793-8.
|
| [10] |
DRÉNO B, KUNSTFELD R, HAUSCHILD A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial[J]. Lancet Oncol, 2017, 18(3): 404−412. doi: 10.1016/S1470-2045(17)30072-4.
|
| [11] |
SAUSSELE S, RICHTER J, GUILHOT J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial[J]. Lancet Oncol, 2018, 19(6): 747−757. doi: 10.1016/S1470-2045(18)30192-X.
|
| [12] |
ATALLAH E, SCHIFFER C A, RADICH J P, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial[J]. JAMA Oncol, 2021, 7(1): 42−50. doi: 10.1001/jamaoncol.2020.5774.
|
| [13] |
ORNSTEIN M C, WOOD L S, ELSON P, et al. A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2017, 35(16): 1764−1769. doi: 10.1200/JCO.2016.71.1184.
|
| [14] |
JAMAL-HANJANI M, WILSON G A, MCGRANAHAN N, et al. Tracking the evolution of non-small-cell lung cancer[J]. N Engl J Med, 2017, 376(22): 2109−2121. doi: 10.1056/NEJMoa1616288.
|
| [15] |
ZHANG J T, LIU S Y, GAO W, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer[J]. Cancer Discov, 2022, 12(7): 1690−1701. doi: 10.1158/2159-8290.CD-21-1486.
|
| [16] |
AI X H, CUI J W, ZHANG J X, et al. Clonal architecture of EGFR mutation predicts the efficacy of EGFR-tyrosine kinase inhibitors in advanced NSCLC: a prospective multicenter study (NCT03059641)[J]. Clin Cancer Res, 2021, 27(3): 704−712. doi: 10.1158/1078-0432.CCR-20-3063.
|
DownLoad: